Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.

Experimental & molecular medicine - 24 May 2018

Jin Junyeong, Park Gunwoo, Park Jong Bae, Kim Soohyun, Kim Hyori, Chung Junho

Abstract excerpt

Antibody-drug conjugates (ADCs) can selectively deliver cytotoxic agents to tumor cells and are frequently more potent than naked antibodies. However, optimization of the conjugation process between antibodies and cytotoxic agents and characterization of ADCs are laborious and time-consuming processes. Here, we describe a novel ADC platform using a tetravalent bispecific antibody that simultaneously binds to the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Bispecific
Share to Cell Death

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cetuximab

Share to Cotinine

Share to Indoles

Share to Single-Chain Antibodies

Share to Tissue Distribution

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29795377
DOI: 10.1038/s12276-018-0096-z
PMCID: PMC5967348

Genes

EGFR
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations.PMID 29795377Read ↗

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer.Semantic proximity Read ↗

Synergistic Approach of Antibody-Photosensitizer Conjugate Independent of KRAS-Mutation and Its Downstream Blockade Pathway in Colorectal Cancer.Semantic proximity Read ↗

ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope.Semantic proximity Read ↗

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.Semantic proximity Read ↗

Recent progress of aptamer‒drug conjugates in cancer therapySemantic proximity Read ↗

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerSemantic proximity Read ↗

A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor specificitySemantic proximity Read ↗

Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transportersSemantic proximity Read ↗

Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantationSemantic proximity Read ↗

Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib.Semantic proximity Read ↗

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells.Semantic proximity Read ↗

In vivo-stable bis-iminobiotin for targeted radionuclide delivery with the mutant streptavidin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.